Clinical and metabolomic characterization of Brivanib‐Induced hypertension in metastatic colorectal cancer

BACKGROUND: Trials of tyrosine kinase inhibitors (TKI) have not demonstrated dramatic benefits in advanced colorectal cancer (CRC), and this may be a function of poor patient selection. TKI‐induced hypertension is reportedly a surrogate marker for treatment benefit for some tumor types. Our objectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Rattner, Jodi I., Kopciuk, Karen A., Vogel, Hans J., Tang, Patricia A., Shapiro, Jeremy D., Tu, Dongsheng, Jonker, Derek J., Siu, Lillian L., O'Callaghan, Chris J., Bathe, Oliver F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469666/
https://www.ncbi.nlm.nih.gov/pubmed/37329221
http://dx.doi.org/10.1002/cam4.6248

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469666/
https://www.ncbi.nlm.nih.gov/pubmed/37329221
http://dx.doi.org/10.1002/cam4.6248

Ejemplares similares